High Quality for Acetaminophen - Doxorubicin Hydrochloride CAS 25316-40-9 API USP Standard Factory High Purity – Ruifu

Manufacturer with High Purity and Stable Quality Chemical Name: Doxorubicin Hydrochloride CAS: 25316-40-9 Antitumor Antibiotic Agent. Inhibits DNA Topoisomerase II API High Quality, Commercial Production

Chemical Name	Doxorubicin Hydrochloride
Synonyms	Doxorubicin HCl; Adriamycin HCL; Hydroxydaunorubicin Hydrochloride
CAS Number	25316-40-9
CAT Number	RF-API38
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C27H30ClNO11
Molecular Weight	579.98
Brand	Ruifu Chemical

Item	Specifications
Appearance	Orange-Red or Red Crystalline Powder; No visible evidence of contamination by foreign matter
Solubility	Soluble in water and methanol; slightly soluble in ethanol; practically insoluble in acetone
Identification A	IR spectrum corresponds to the IR spectrum of the reference standard
Identification B	The retention time of the doxorubicin peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
pH	4.0~5.5
Water Content	≤4.0%
Related Substances
Impurity A (Doxorubicinol)	≤0.50%
Any Other Unknown Impurity	≤0.20%
Total Unknown Impurities	≤0.50%
Total Impurities	≤1.0%
Assay	98.0%~102.0% of C27H30ClNO11 calculated on the anhydrous, solvent-free basis
Residual Solvents
Acetone	≤0.50%
Acetone + Ethanol	≤2.5%
Methanol	≤0.30%
Dichloromethane	≤0.06%
Test Standard	United States Pharmacopeia (USP) Reference Standard
Usage	Active Pharmaceutical Ingredient (API)

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation. Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Doxorubicin Hydrochloride (CAS: 25316-40-9) with high quality. Doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy. Doxorubicin is a potent antitumour agent active against a wide spectrum of malignancies, including leukaemias, sarcomas, breast cancer, small cell lung cancer and ovarian cancer. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. Doxorubicin does not playa crucial role in the treatment of tumours that can be cured with chemotherapy, such as testicular carcinoma, nephroblastoma, Burkitt's tumour and choriocarcinoma^[3]. Like most other cytostatic agents, doxorubicin is not effective in the most frequently occurring malignancies such as colorectal cancer and non-small cell lung cancer.